Extended Data Fig. 8: 89ZED880082A/CED88004S pharmacokinetics and integrity.
From: Whole-body CD8+ T cell visualization before and during cancer immunotherapy: a phase 1/2 trial
a, b, Time-concentration profiles (mean ± standard deviation) of 89ZED88082A/CED88004S serum protein and radioactivity following a single IV infusion of a, 4 mg (n = 3) and b, 10 mg (n = 6). c, Time-concentration profile (mean ± standard deviation) of 89ZED88082A/CED88004S pretreatment and during treatment in the presence of immune checkpoint inhibitor antibodies. d, Representative integrity assay (SDS-PAGE combined with autoradiography) of 89ZED880082A in urine and serum in samples drawn after 30 min and 2, 4, and 7 days after tracer injection (n = 3).
